Layolis Fe is a microdose chewable birth control. This drug contains norethindrone, ethinyl estradiol and ferrous fumarate. It is prescribed to prevent pregnancy.
Indications for use
Mechanism of action
Layolis Fe is characterized as a combined oral birth control containing ethinyl estradiol and norethindrone. At a therapeutic dose, norethindrone also has antiandrogenic and weak anti-mineralocorticoid characteristics. This birth control drug is prescribed to prevent pregnancy by suppression of an ovulation. It also changes the viscosity of cervical secretions which complicates the penetration of spermatozoa into the uterine cavity. It prevents the attachment of fertilized egg to the fallopian tubes. There is evidence of the risk reduction of endometrial and ovarian cancer when a woman takes combined oral contraceptives.
Mode of application and dosage
Layolis Fe is prescribed for a daily application. It should be taken orally. The course includes 28 pills. Active ingerdients: norethindrone and ethinyl estradiol are contained in 21 pills. The latest 7 pills contain ferrous fumarate. Every pill is intended to be taken at one and the same time. A pill is washed down with a full glass а water. When you start taking placebo pills your periods will come. If you have not observed periods within 2 months of taking this medication it is necessary to contact a doctor to exclude pregnancy. If you are vomiting or suffer from nausea it is necessary to protect yourself with backup means (condoms or suppositories).
As any other birth control medications, Layolis Fe has contraindications about which a doctor should inform a woman. If you have any of this diagnosis it is necessary to change the birth control. The main contraindications are:
- hypersensitivity to the drug ingredients;
- the presence of vein thrombosis, deep vein thrombosis, pulmonary embolism currently diagnosed or prior transferred;
- the presence of arterial thrombosis including of myocardial infarction currently diagnosed or prior transferred;
- thrombosis precursors including transient ischemic attack, stenocardia as well found in the medical history;
- cerebrovascular diseases currently or in history;
- complicated valvular heart disease, atrial fibrillation;
- arterial hypertension of uncontrolled character;
- severe surgical intervention complicated by the extended impossibility to move;
- smoking over 35;
- the presence of severe or multiple risk factors for arterial thrombosis like diabetes mellitus with vascular complications, severe arterial hypertension, severe dyslipoproteinemia;
- pancreatitis inclusively of a history of severe hypertriglyceridemia;
- hepatic failure;
- benign or malignant hepatic tumors diagnosed currently or found in the history;
- severe hepatic disease diagnosed now or transferred in the medical history;
- severe chronic kidney failure or acute kidney failure;
- malignant diseases of the reproductive system (genital organs, mammary glands) provoked by hormone-dependent causes;
- vaginal bleeding of unknown etiology;
- migraine complicated by focal neurological symptoms found in medical history;
- suggested or diagnosed pregnancy;
- lactation period;
- hereditary intolerance to galactose, lactase deficiency, glucose-galactose malabsorption.
- Nervous system: headache, emotional lability, depression; decreased libido; increased libido.
- Endocrine system: menstrual cycle violations, intermenstrual bleeding, pain in the mammary glands; secretion from the mammary glands.
- Senses: hearing loss, poor contact lenses tolerance.
- Digestive system: nausea, abdominal pain, vomiting, diarrhea.
- Skin and subcutaneous tissue: pruritus, acne, eczema, urticaria, skin rash, erythema nodosum, erythema multiforme, chloasma.
- Vascular system: migraine; increase or decrease in blood pressure; venous and/or arterial thrombosis, thromboembolism.
- Systemic disorders and complications at the injection site: an increase in body weight; fluid retention; weight loss.
- Immune system: bronchospasm or some other respiratory problems.
- Reproductive system and mammary glands: acyclic vaginal bleeding, tenderness, enlargement of the mammary glands, vaginal candidiasis; vaginitis; allocations from the mammary glands, an increase in vaginal secretion.
The interaction of oral contraceptives with other drugs (enzyme inducers, some antibiotics) can stimulate breakthrough bleeding and/or influence on the contraceptive effectiveness in the form of reduction.
Some medications may decrease contraceptive reliability. The list of this drugs is the following primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, rifabutin, ritonavir, nevirapine, penicillin, tetracyclines, griseofulvin. The medications used mainly in the treatment of depressed mood may also decrease the contraceptive reliability of Layolis Fe.
What if I miss a dose?
If the delay in taking the pill was less than 12 hours, there is no reduction in the contraceptive protection. A woman needs to take a pill as soon as possible, the next going pills are taken at the usual time. If the delay in taking the pills is more than 12 hours, there is a reduction in the contraceptive reliability. Backup means are recommended to protect from unwanted pregnancy.
Layolis Fe and pregnancy
Layolis Fe is contraindicated during pregnancy as it may provoke developmental defects in the fetus. It is also recommended to withdraw the birth control as it may change the composition of the breast milk.